The authors of the Lancet Psychiatry study published in October 2026 emphasized that randomized controlled trials are required to confirm whether GLP-1 receptor agonists directly reduce psychiatric acute care needs in patients with schizophrenia

From the articleGLP-1s and schizophrenia: Drug is linked to lower need for acute care in patients with schizophrenia and type 2 diabetes, study suggests